Named after the hundred-eyed watchman of Greek myth, Argus watches the education landscape: spotting new opportunities, pressure-testing the ventures we're building, and tracing every read back to the real-world signals behind it.
The evidence library: the raw signals the pipeline is watching across the education ecosystem. Every idea is built from these.
Doctronic acquired Summer Health to expand into pediatric care and strengthen its AI-powered primary care platform. The post Doctronic Acquires Summer Health to Expand into Pediatric Primary Care appeared first on MedCity News .
With the merger, Processa’s new lead asset is a Vidya Therapeutics immunology drug that offers pipeline-in-a-product potential addressing a target that has clinical and regulatory validation from a recently approved Novartis drug. Vidya’s molecule is a next-generation drug that could have advantages over Novartis’s pill. The post Processa Acquisition Lands Immunology Drug That Could Rival a New Novartis Product appeared first on MedCity News .
A survey of 112 health system executives finds that Epic’s hold on hospital IT keeps getting stronger — but startups still have a shot, provided they solve a specific problem, prove strong ROI or offer a product that Epic is lagging behind on. The post Epic-First Doesn’t Mean Epic-Only: Where Hospitals Are Still Buying from Startups appeared first on MedCity News .
CMS’s new framework sounds like a gentle opt-in. There’s no requirement to meet every standard on day one, just a commitment to work toward doing the right thing. That sounds great. But to actually participate in the network, you have to meet a baseline level of interoperability. The post A New Era of Interoperability, But Who Gets Left Behind? appeared first on MedCity News .
The most common and most expensive misunderstanding in healthcare cloud strategy is treating the cloud as a destination you either reach or you do not, when it is really a progression through five distinct stages, each one unlocking capabilities the stage before it could not support. The post The Healthcare Cloud Maturity Model: The Five Stages Most Health Systems Skip appeared first on MedCity News .
Onos Health’s Series A funding round was led by Costanoa, with support from Flare Capital Partners and CVS Health Ventures. The post Onos Health Raises $17M to Expand AI-Powered Behavioral Health Platform appeared first on MedCity News .
Boston Scientific disclosed a cyberattack disrupting its global IT systems and order shipping capabilities, with the company unable to provide a timeline for when normal operations will resume. The disclosure adds the medical device giant to a growing list of medtech companies — including Stryker, Medtronic and Abbott — hit by major cyberattacks this year. The post Cyberattack Disrupts Boston Scientific’s Operations: 7 Things to Know appeared first on MedCity News .
FDA approval of Revolution Medicines’ daraxonrasib, brand name Rasonque, makes the molecule the first RAS inhibitor approved for treating pancreatic adenocarcinoma, the most common type of pancreatic cancer. The speedy regulatory nod specifically covers advanced cases of this type of cancer, which has had limited treatment options. The post Revolution Medicines Receives Landmark FDA Drug Approval in Pancreatic Cancer appeared first on MedCity News .
Health-tech pilots don’t usually fail because the product is bad. They fail because the system was never wired to absorb it. The post Stop Pitching the Institute — Pitch the Stack appeared first on MedCity News .
A new class action lawsuit accuses Oura of overstating its smart ring’s sleep tracking accuracy, arguing the device relies on AI-generated estimates rather than the clinical measurements needed for true sleep staging. The case is reigniting questions about how much precision consumers should expect from AI-powered health wearables. The post Why Oura’s Sleep-Tracking Lawsuit Is Really About Trust appeared first on MedCity News .
GSK drug Jideytro received FDA approval for treating advanced cases of non-small cell lung cancer driven by ROS1 alterations. This molecule came from Nuvalent, which GSK recently acquired for $10.6 billion. The post $10B M&A Deal Pays Off With GSK’s First Lung Cancer Drug Approval appeared first on MedCity News .
Headspace announced partnerships with Charlie Health, Cortica, Prosper Health and Equip. The post Headspace Teams Up with 4 Companies for Specialty Care appeared first on MedCity News .
Women have to navigate the fragmented system with very little support, coordinating between providers and often interpreting conflicting guidance. The post Hidden in Plain Sight: The Cost Crisis in Women’s Healthcare appeared first on MedCity News .
At the end of the day, the most important question is a simple one: Do you actually know if you’re being reimbursed correctly? The post What Healthcare Organizations Miss When It Comes to Reimbursement Accuracy appeared first on MedCity News .
The policy conversation needs to shift from just deprescribing alone to building the clinical infrastructure that delivers consistent, high-quality behavioral health care. The post Better Prescribing, Not Less Prescribing, Is What Behavioral Health Needs appeared first on MedCity News .
Happy Health’s $75 million round was from ARCH Venture Partners and OpenLoop. The post Happy Health Snags $75M to Support Home-Based Care appeared first on MedCity News .
Merck and Moderna said intismeran autogene, an mRNA cancer vaccine that prompts an immune response to proteins expressed by a patient’s tumors, met the main goal of a pivotal test in melanoma. It’s the most advanced trial in a 50/50 partnership evaluating the personalized cancer treatment in a wide range of tumor types. The post Merck, Moderna Personalized mRNA Cancer Therapy Achieves a First for Melanoma appeared first on MedCity News .
The next healthcare revolution isn’t about treating osteoporosis, it’s about preserving mobility and healthspan. The post Why Bone Health Is Preventive Healthcare’s Next Big Category appeared first on MedCity News .
The 1842 Fund launched a new startup called Suvi Health, which is developing an ambient AI platform that records hospital bedside conversations and turns them into a shared task list for patients and families. The company will pilot the tool with Mayo Clinic starting next month. The post New Startup Launches to Close the Bedside Communication Gap in Hospitals appeared first on MedCity News .
A new survey finds that employers are moving away from the Big Three PBMs while prioritizing healthcare affordability and transparency. The post Report: Employers’ Use of Big Three PBMs Falls in 2026 appeared first on MedCity News .
Deerfield Management formed Boulevard Bio with scientific co-founders Georg Schett and Frank Nestle. The startup’s lead program is in early clinical development for an autoimmune kidney disorder, and could offer dosing advantages over a recently approved Vera Therapeutics medicine and a Vertex Pharmaceuticals drug currently under FDA review. The post Startup Boulevard Bio Launches With Immune Reset Pioneer Schett as Co-Founder appeared first on MedCity News .
While organizations have invested heavily in expanding ambulatory networks, many are discovering that operational workflows have not evolved at the same pace. The result is a growing gap between demand and the systems designed to manage it. The post Ambulatory Growth Demands a New Operating Model appeared first on MedCity News .
Revenue cycle vendor Unlimited Technology Systems disclosed a ransomware attack affecting 3.8 million patients — the second-largest healthcare data breach reported to HHS this year. The post Health IT Vendor’s Data Breach Exposes Nearly 4M Patient Records appeared first on MedCity News .
UnityPoint Health’s chief medical officer, Gregory Johnson, shared several ways the system is using AI to lift administrative burden off clinicians and get them back to patient care — including ambient scribing, real-time capacity tracking and AI-powered chart review. The post 6 Ways UnityPoint Health Is Trying to Make Clinicians’ Jobs Easier appeared first on MedCity News .
Curative Insurance Company partnered with Wondr Health to expand weight management support for its members. The post Curative, Wondr Health Team Up for Weight and Metabolic Health Support appeared first on MedCity News .
Attovia Therapeutics’ biologic medicines could offer advantages over currently available immune disorder drugs, such as Sanofi’s blockbuster medicine Dupixent. The IPO comes as Attovia looks to expand clinical development of its pipeline in 2027. The post Attovia’s Upsized IPO Brings In $289M to Fund New Kind of Biologic for Immune Disorders appeared first on MedCity News .
Despite the silk masks, oils, and sleepy girl mocktails swirling around social media, one of the greatest causes of non-restorative sleep is rarely mentioned by wellness influencers online: actual sleep disorders. The post The Sleep Crisis We May Be Missing: Why Millions of Americans Remain Undiagnosed appeared first on MedCity News .
Healthcare leaders who shape that future need more than innovation. They need a visible, credible voice that helps the people around them — patients, clinicians, employees, partners, and investors — understand what the change is, why it matters, and why this is the right person to lead it. The post The Healthcare Leaders Driving Change Need to Get Better at Explaining It appeared first on MedCity News .
QuantHealth raised $45 million in Series B funding to expand its AI platform, which simulates clinical trials before they run and predicts patient outcomes for pharma companies. The startup is aiming to cut the industry’s 90% trial failure rate and speed up the timelines for effective drugs to reach the market. The post QuantHealth Snags $45M to Simulate Clinical Trials Before Patients Ever Enroll appeared first on MedCity News .
Selio Medical developed an FDA-cleared hydrogel device that seals CT-guided lung biopsy punctures before they can cause pneumothorax — a collapsed lung complication that affects up to a third of the 800,000+ such biopsies performed annually in the U.S. The post This Device Could Prevent Lung Biopsy’s Most Common — and Costly — Complication appeared first on MedCity News .
Thyme Care’s Series E round was led by Morgan Health and included participation from Humana, CVS Health Ventures, AlleyCorp, HealthQuest Capital, Foresite Capital, Concord Health Partners, Frist Cressey Ventures, Town Hall Ventures and a16z Bio + Health. The post Thyme Care Raises $125M, Launches New Oncology Parent Entity appeared first on MedCity News .
In a mid-stage study, Teva’s drug prevented intestinal damage in celiac disease patients who underwent a gluten challenge — eating food with gluten to see if it prompts an immune response. There are currently no FDA-approved drugs for celiac disease, but Teva’s antibody is part of a competitive race to bring patients the first one. The post Teva Drug Rises to the Gluten Challenge, Stopping Intestinal Damage in Celiac Disease Trial appeared first on MedCity News .
[Sponsored] We have the opportunity to design systems that give people greater capacity for the work where human presence matters most: listening, understanding, reassuring, deciding, and caring. The post Automation Didn’t Dehumanize Care. Bad Systems Did. appeared first on MedCity News .
Isolated improvements rarely translate into enterprise-wide transformation when they are layered onto outdated, inefficient workflows instead of being integrated into redesigned care delivery. The post The Healthcare Inflection Point: AI Can’t Fix 1990s Technology appeared first on MedCity News .
Throne Science — a startup selling an AI-powered toilet camera that tracks gut health, hydration and urinary function — closed a $10 million Series A funding round. CEO Scott Hickle said the goal is to become a “smoke detector for colorectal cancer,” filling a monitoring gap he noted the wearables industry has largely ignored. The post Smart Toilet Sensor Startup Is Flush with $10M Funding appeared first on MedCity News .
Included Health announced plans to acquire Firefly Health to accelerate its alternative health plan strategy for employers. The post Included Health to Acquire Firefly Health to Expand Alternative Health Plan Offering for Employers appeared first on MedCity News .
Altimmune’s pemvidutide achieved a statistically significant reduction in heavy drinking days compared to a placebo in a Phase 2 trial. This peptide drug, which is designed to activate the GLP-1 and glucagon receptors, is also on track to begin a pivotal test in the fatty liver disease MASH. The post Altimmune’s GLP-1 Drug Reduces Heavy Drinking in Alcohol Use Disorder Trial appeared first on MedCity News .
Done well, NICU UM is so much more than an approval process. It is a clinical credibility engine that — when integrated with Case Management (CM) — drives every NICU admission toward the most appropriate, impactful care. The post Why Specialized UM Delivers on Every NICU Outcome appeared first on MedCity News .
A few minutes of interaction with a digital tablet and speaking can reveal patterns that once required advanced imaging, years of observation, or were just completely undetectable. The post Spotting Alzheimer’s Years Earlier Through AI and Clinically Meaningful Insights appeared first on MedCity News .
Employers expect healthcare costs to rise 9.2% in 2027 as they seek ways to curb rising hospital and pharmacy costs. The post Business Group on Health: Employer Healthcare Costs Projected to Rise 9.2% in 2027 appeared first on MedCity News .
Johnson & Johnson antibody drug Imaavy expanded its label to include the treatment of warm autoimmune hemolytic anemia (wAIHA). Projected to become a blockbuster seller across multiple indications, Imaavy was first approved last year for treating generalized myasthenia gravis. The post J&J’s Imaavy Becomes First FDA-Approved Therapy for Rare Form of Anemia appeared first on MedCity News .
Here’s how finance leaders can evaluate AI investments in revenue cycle management before committing budget, and the risk exposure most vendor pitches leave out. The post Before You Sign That AI Contract: 7 Questions Every Healthcare CFO Should Ask appeared first on MedCity News .
Prediction market Kalshi launched betting markets tied to clinical trial results and FDA approvals. Healthcare leaders warn the model could invite insider trading and distort the integrity of the research outcomes it’s meant to forecast. The post You Can Now Bet on Clinical Trials Like Playoff Games, But Health Execs Say It Crosses a Line appeared first on MedCity News .
Rep. Angie Craig introduced a bill to establish a public health insurance option on the ACA marketplaces and permanently extend enhanced premium tax credits. The post New Bill Seeks to Create Public Option on ACA Marketplaces appeared first on MedCity News .
Agios Pharmaceuticals said tebapivat fell short of expectations in a Phase 2 test in sickle cell disease. It’s the latest in a series of disappointing industry developments in sickle cell disease. The post Agios Pharma Drops Sickle Cell Disease Drug After Phase 2 Data Disappoint appeared first on MedCity News .
Screening for mental health symptoms in patients with significant allergic disease is not overreach The post How Diagnostic Precision in Allergy Care Supports Mental Well-Being appeared first on MedCity News .
Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction. The post Why Pharma Companies Should Look To Social Media For Better Patient Insight appeared first on MedCity News .
[Sponsored] A five minute survey from MedCity News asks payers what they think of AI and how it is being implemented. Participate today and we will reward you! The post Where Will AI Deployment Benefit Payers the Most? appeared first on MedCity News .
Included Health is partnering with Carrum Health to provide high-quality specialty care while reducing costs for employers. The post Included Health Taps Carrum Health for Value-Based Specialty Care appeared first on MedCity News .
Amylyx Pharmaceuticals’ avexitide led to statistically significant and clinically meaningful reductions in hypoglycemic events in patients with post-bariatric hypoglycemia (PBH). This peptide drug, a GLP-1 antagonist, was acquired from Eiger BioPharmaceuticals in 2024. The post Amylyx Plans FDA Filing After GLP-1 Drug Hits Trial Goals in Rare Metabolic Condition appeared first on MedCity News .